Tube Tug-of-War: keeping or removing drain during pancreatic surgery may cut complications
NCT ID NCT07532759
First seen Jun 25, 2026 · Last updated Jul 16, 2026 · Updated 3 times
Summary
This trial looks at whether keeping or removing a drainage tube (PTCD catheter) during pancreatic surgery leads to fewer complications. About 100 patients with jaundice from tumors will be randomly assigned to one of two groups. The main goal is to see which approach reduces serious problems like bile leaks and other major complications within 90 days after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PTCD catheter (a drainage tube placed before surgery to relieve bile blockage)
- What this could lead to
- If this trial succeeds, it could guide surgeons on whether to keep or remove the PTCD tube during pancreatic surgery, potentially reducing serious complications like bile leaks.
- What could go wrong
- This is an early exploratory trial with only 100 participants, so results may not apply to all patients. The study compares two surgical approaches, not a new drug, so the impact is limited to surgical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ultrasound inside the body reveals how tumors block the bile duct
- Immunotherapy-Chemo cocktail shows promise for Hard-to-Treat bile duct cancer
- New oxygen method may prevent dangerous drops during ERCP
- New drug targets hard-to-treat cancers in early trial
- Supercharged immune cells take on bile duct cancer in early trial
- Immune cells take on rare bile duct cancer in early trial